Tag: News Approved

Posted on

Opinion: American horses are obese, too

The horses in America are getting fat. They are trying to tell us something.

Fifty-one percent of mature light-breed horses in the United States are obese — a rate that ranks among the world’s highest, slightly above Britain and nearly twice that of Australia or Denmark. That figure comes from a peer-reviewed prevalence study, and it sits alongside a number that should give any clinician pause: The U.S. also leads the G7 in human obesity. The same country. The same epidemic. A completely different species.

Read the rest…

Posted on

Opinion: $2 million gene therapy cures require a financing model

A new class of medicines is transforming health care. Gene therapies can now cure diseases like sickle cell with a single treatment, but they come with a price tag that would have been unthinkable a decade ago — often $2 million or more per patient.

In a way, this cost makes sense: These are potential cures that can avoid years of hospitalizations, complications, and lost productivity. In many cases, they concentrate decades of value into a single intervention.

Read the rest…

Posted on

When it’s time to save a limb, novel clinic meets unhoused people where they are 

BOSTON — Carlton Haynes hugged his left knee, pulling it toward his shoulder as hard as he could. He was desperate to blunt the pain shooting from an open, oozing wound on his right shin. Anahita Dua, a vascular surgeon leading an unusual clinic created by Massachusetts General Hospital that Saturday, told him he was going to the ER and then the OR, where she would remove damaged skin and treat the wound. 

Without this stopgap measure, she warned him, he’d almost certainly need amputation. OK, he said, but first he wanted a smoke. 

Read the rest…

Posted on

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Nature Medicine, Published online: 07 June 2026; doi:10.1038/s41591-026-04479-3

As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).

Posted on

STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA

You’re reading the web edition of STAT’s ADA in 30 Seconds newsletter, from the American Diabetes Association’s annual conference. 

Welcome to the third and final edition of STAT’s ADA in 30 Seconds newsletter.

Elaine Chen starts us off with updates on the competitive climate for obesity drugs and I’m relaying insights on eating disorders, new word on a BCG vaccine, and a clarification from ADA on Friday’s police incident.

Continue to STAT+ to read the full story…